Skip to content
2000
Volume 15, Issue 2
  • ISSN: 1573-4129
  • E-ISSN: 1875-676X

Abstract

Background: Lamivudine was approved by Food and Drug Administration of the United States for the treatment of both HIV and HBV infection, which has been widely used as monotherapy or a component of combination therapy in clinics in many countries and nationalities. Methods: In this paper, the recent chromatographic and mass spectrometry analytical methods for the determination of lamivudine individually or combination with other drugs simultaneously were presented. These methods were widely applied in pharmacokinetics studies, bioequivalence studies, therapeutic drug monitoring studies, cell and animal experiments. Conclusion: The review paper might provide references for determining lamivudine in biological fluids, the intracorporal process of lamivudine, and the clinical practice by monitoring plasma concentration of lamivudine in the future.

Loading

Article metrics loading...

/content/journals/cpa/10.2174/1573412913666171017150427
2019-04-01
2025-09-10
Loading full text...

Full text loading...

/content/journals/cpa/10.2174/1573412913666171017150427
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test